Biological Information

Background Information:

Dopamine receptors belong to the superfamily of G protein-coupled seven transmembrane proteins. G-protein-coupled receptors constitute one of the major signal transduction systems in eukaryotic cells. Coding sequences for these receptors, in those regions believed to contribute to the agonist-antagonist binding site, are strongly conserved across mammalian species. Various members of the dopamine receptor family are generally classified as either ‘D1-like’ or ‘D2-like’. D2-like receptors comprise the D2, D3 and D4 receptors, which inhibit activation of adenylate cyclases via coupling to G1/G0 protein.

No. of Assays on Panel:

2

Assays on Panel:

Family

GPCR

Name

Item

310600-0

Protein

D4

Organism

Human

Assay Sub Type

GTPgammaS

Family

GPCR

Name

Item

310600-1

Protein

D4

Organism

Human

Assay Sub Type

GTPgammaS

Family:

GPCR

Sub Family:

Dopamine

Class:

Class A

Protein Name:

D4

Uniprot Number:

P21917

Gene Name:

DRD4

Gene ID:

1815

Gene Aliases:

DRD1B

Accession Number:

NM_000797

Organism:

Human

Construct Details:

Full Length, Recombinant

Cell Type:

CHO-K1

Assay Information

Assay Type:

Functional

Assay Sub Type:

GTPgammaS

Functional Mode:

Agonist & Antagonist

Detection Method:

Radiometry

Measured Response:

Scintillation

Testing Information

Procedure Summary:

Human recombinant dopamine D4.4 receptors expressed in CHO-K1 cells are used. Test compound is preincubated with 0.1 mg/ml‡ membranes and 10 µM GDP for 20 minutes at 25°C in modified HEPES buffer pH 7.4 and SPA beads are then added for another 60 minutes at 30°C. The reaction is initiated by 0.3 nM [35S]GTPgS for an additional 30 minute incubation period. Test compound-induced increase of [35S]GTPgS binding by 50 percent or more (≥50%) relative to the 300 µM dopamine response indicates possible dopamine D4.4 agonist activity. Test compound-induced inhibition of 1 µM dopamine-induced increase of [35S]GTPgS binding response by 50 percent or more (≥50%) indicates receptor antagonist activity. Note: ‡Membrane protein may change from lot to lot, the concentration used will be adjusted if necessary.

Incubation:

30 min at 30°C

Control Inhibitor:

Spiperone

Control Activator:

Dopamine

Criteria For Significance:

≥ 50% Increase in bound [35S]GTPgammaS relative to dopamine response, ≥ 50% Inhibition of dopamine-induced bound [35S]GTPgammaS

Test Concentration / Dose:

Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM

Test Sample Requirements:

75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)

Minimum Order Quantity:

16

Turnaround Time

Standard:

20 Business Days

Reference Compound Data

PubChem ID

681

Name

Dopamine

Measurement

0.22μM - EC50

PubChem ID

5265

Name

Spiperone

Measurement

0.0008μM - IC50

Clinical Relevance

Therapeutic Area:

CNS/Addiction/Pain

Adverse / Beneficial Action:

Dopamine D4 receptor antagonism may be useful in the treatment of psychosis, possibly without causing tardive dyskineasia and hyperprolactineamia; receptor antagonism has also been reported to reduce novelty seeking. No major pharmacological differences have been reported for the most common variants of this receptor (D4.2, D4.4 and D4.7).

Additional Information

Brand:

LeadHunter

Testing Location:

Taiwan - Taipei

RELATED SOLUTIONS

Item: 310500
Item: 310700
Item: 310500-0
Item: 310600-0
Item: 310700-0
Item: 310500-1
Item: 310600-1
Item: 310700-1
Item: 220000
Item: 220100